Supernus to Participate in Annual Piper Sandler Healthcare Conference
November 18 2020 - 10:00PM
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases, today announced
that the Company's management will participate in a fireside chat
as part of the Piper Sandler 32nd Annual Virtual Healthcare
Conference, being held December 1-3, 2020. The Company will also
host investor meetings on Thursday, December 3, 2020.
The pre-recorded fireside chat can be accessed
beginning November 23, 2020 by visiting Events & Presentations
in the Investor Relations section on the Company's website at
www.supernus.com. An archived replay of this fireside chat will be
available for 60 days on the Company's website after the
conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company
focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases. The Company
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR®
(extended-release oxcarbazepine) for the treatment of epilepsy;
APOKYN® (apomorphine hydrochloride injection) for the acute
treatment of hypomobility in advanced Parkinson’s disease (PD);
MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical
dystonia and treatment of chronic sialorrhea in adults; and XADAGO®
(safinamide) as an adjunctive treatment to levodopa/carbidopa in PD
patients with hypomobility. The Company is also developing several
product candidates to address large market opportunities in the CNS
market, including SPN-812 for the treatment of ADHD; SPN-830
(apomorphine infusion pump) for the continuous treatment of motor
fluctuations (“on-off” episodes) in PD; SPN-820 for
treatment-resistant depression; and SPN-817 for the treatment of
epilepsy.
See full Prescribing Information for our products here: Trokendi
XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.
All trademarks are the property of their respective owners.
CONTACTS:Jack A. Khattar, President and CEO
Jim Kelly, EVP & Chief Financial Officer
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Sep 2023 to Sep 2024